Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.
Also called NCT02690974
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose supportive care
- Phase
- Phase 4
- Enrolled
- 302 participants
- Sponsor
- Registry
-
NCT02690974
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02690974. Allocation not applicable; no masking; primary purpose supportive care. Start 2016-03-08 (actual); primary completion 2017-06-07 (actual). Results posted on 2019-06-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
- Acronym
- PARASAIL
- Condition
- Hearth Failure With Reduced Ejection Fraction (HFrEF)
- Intervention (Drug)
- LCZ696 (sacubitril/valsartan)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02690974- Content hash
61291947ec4c0670836ed6facdb82c45e0c60a155da426d4ebb3dda762888b3d